related an afternoon, surgery. But progress on advanced year. second and team [ph], last Hunter provide mission make everyone, implantable thank for Today the device patients October. following outcome a to our good to IPO public to us. joining medicine Undoubtedly, our and products Thanks, call you marks company earnings has was as meaningful continued in undergoing Aziyo our extraordinary the regenerative improve XXXX
best and and this the proprietary medical understanding on optimize implantable to factors science matrices cells, products. through unique designed our complications are the products devices. tissue of the our related to our to growth reduce do Our based with platforms associated We the deep structural
Our address pacemakers, tissue and primary defibrillators; procedures; bone electronic and orthopedic markets: reconstruction. and implantable as spine core product such platforms or repair soft three devices,
business. V as tissue questions. to I'll go leverageable we provide progress open a enter accomplishments fulfill will prepared processing our highly XXXX, we Moldable. market new remarks priorities financials and current our In my more facility and considerable multiple our market our contracts XXXX. Additionally, for and In cover of through as recent call Richmond then highlights California Matt today, the detail and and bringing including of and made up into we'll component products, on manufacturing guidance to view the we OsteGro ViBone a your
notably CanGaroo Envelope most to pipeline achieve new release our products, initiate clinical a to targeted study advanced of demonstrate antibiotic also benefits [ph] We the and completing a products. feasibility our our for studies
our We X,XXX hospitals, channel providers reach through more also a United and to strengthened Scientific, Late in and CanGaroo such and partnerships the Boston leaders Premier with access organization our than year, our granted with as Biotronik. Envelope States. the expanded our the industry, commercial technology XXX,XXX we to in in Medtronic expanded other that contract breakthrough
to brought new the the Jerry also deep as that and billion space. members will our disrupt our CMO as board leadership Riebman, We our Matt with of course, funds we to $X and completed in IPO, regenerative the Brigid which medicine experience in continue enable And Jordan adding sector: CFO we Dr. Maybelle Makes. healthcare us team, our secured and had two
challenges XXXX. quarter our team X% over million, the of the revenue a financial was year-over-year XX% a current environment, to Aziyo again revenue million, quarter product highlights the to Turning delivering fourth once during a increase the of representing and $XX.X increase. fourth increase of Core $XX.X over briefly of third the rose the XXXX recent X% quarter,
business our year-over-year. challenges accomplishment year. XX% Quite the For product of grew an full-year, the the considering core throughout COVID of much revenue
with finished year our announced Turning we us meaningful greater number to even initiatives the devices, have to key implantable States our of that market around in procedures opportunity United business recently for market XXXX. our on XXX,XXX confidence highlights. our the differentiated We performed products in million, strong regenerative progress the address and medicine a and an portfolio. Started give opportunity $XXX represents in with electronic believe
a of number important milestones. met recently have We
complications device-related only the the for that for healing biological in and pocket forms healthy of implantable regulate vascularized stimulate solution primary market a response is envelope electronic this the CanGaroo, commercially holding devices natural available systemically formation Our to tissue.
splendid limited centers. we As to than year our well, Scientific more and our benefit mix and adds a served medical key reminder, go-to especially sales support with includes Biotronik, agreements partners' for throughout professionals. from strategy access of sales the Boston direct which and where access was relationships us a market partnership no commercial broad hospital This past approach X,XXX and
this has are onboarding included progress by year-end salesforce new we and remained organization direct the also productive sales At Our recent reps. dedicated to reps. encouraged our XX made market XXXX, in
development is as of program add sales additional to we continue approach XXXX CanGaroo. the plan towards of with antibiotics selectively headcount our with second throughout half more pipeline year Our adding hiring to targeted the milestones heavily-weighted to
As Premier with the in December noted CanGaroo became earlier, sniffling for designation the effective States which the breakthrough X, United market expanded XXXX.
recently this a additional have traction make can and within to early CanGaroo for in commercial announced us this new more as valuable We and as broadening value accelerate our forward are our contracts CanGaroo. reach, developments pleased accounts now relationship ordering safety for in Premier several of contribution three our the the We look validation patients. partnership. gives enables it accounts exciting to and We with result progress offers obtaining
further for infections post-op received CanGaroo and now natural patients. to approval to biologic This envelope we We're as an be on pleased important solution. deliver approval to also market First, the reduce January, hydration very instructions with to is this that the Mark differentiates the take CE enhancement include the antibiotic able customers it and potential that include in European to with label only to CanGaroo the antibiotic gentamicin.
In partnered Envelope. advance design adding with by and look and be collection to complete track We studies. addition, were through you to data to we platform, CanGaroo on in-vitro antibiotics which updating by manufacturing with to in-vivo our will rifampin, Biotech generation effort, next the progress. followed In forward the the minocycline. to We validation, Cook we've enhanced this delighted for product achieve remain
Our of the XXXX, anticipated in goal remains the submission prepare launch QX FDA half product in with to antibiotic for data XXXX. second CanGaroo with
or the On in implantation biologic a CID no enrolled electronic that patients or the investigate had devices surgery. of study study for time with CIDs Tyrx out implant, revision or focuses an Study procedure and XXX of who recently time envelope, are can returning multicenter year taken announced CanGaroo a contributions a biopsies States adding The is tissue and front, cardiovascular Hill study the of procedure. first treated healing the of tissue the the have soft clinical envelopes the around device implantation patient least characteristics potential at that validate study to implants at of revision the has without identifying in the their effects significant patients. who of This Medtronic's time on we provide to of with envelope implantation. change envelope our for Envelope, for are CanGaroo implantable the clinical placed using went to around at United a change at out We for patients believe previously
repair and with Now billion and an procedures million materials. in the approximately market, turning opportunity orthopedic repair market, bone next $X.X to repair product spine market and $X estimated group our spine using orthopedic
RV agnostic in In consists surgery commercial in this and XXXX, we [ph]. partners platform completed our first market, one cell ViBone bone launch January via Holdings to Moldable, this which supply of product Our Surgalign. Surgalign of announced the market fiber using
procedures enough market fiber from market, continue a lastly, to when performance not the dermis. original product the we group to repair native opportunity In third estimate generating tissue cell roughly human reconstruction. to soft We XXX,XXX characteristics. $XXX procedure. additional tissue addition, using with by is our on this substantial be with arrive expand of Complications Medtronic the million annually partner area our revenues to work data And products
enables Our SimpliDerm closely a decellularizes, patented to resemble, through more is process that natural-occurring tissue. the manufactured product product be
clinical be represent building systems X, Purchasing market the more Group. working Effective today, HealthTrust across evidence, health States. access. than and product X,XXX hospitals on with will contract March as member in are on We the well expanding facilities as HealthTrust's awareness SimpliDerm United
we've We direct made core distributor and offering. driving advancing positive In physician partners are and product our topline this product sales parallel this continuing of summary, performance our are through in pipeline customers strong platforms feedback progress growth. the while substantial on organization to see of providing and growth
we more healthcare leverages to while see predictable not business business Turning party result, product available growth. business quarter a return facility to to our of growth. new and offer part in the in It contract that good revenue a has fourth drive several of range contracts of for bottom also our The this our our core to tissue source manufacturing, efficient of possibly where it manufacturing capacity stable, to to in our expect platforms. contract third companies. positively begin benefit cash line. our We augment a processing the core manufacturing Overall, as as contributes growth capital is a also quite the and additional further is potential
XXXX, As all growth we another we year strong lines. of are entered product poised believe across we for
realize penetrate revenue our core pipeline products. see Although headwinds presence, growth about that the new investments believe these very result benefit in on potential country, technologies an of the be through and to achieved, start on-market across we we'll target sustained we're excited presented returns the commercial our and COVID due and challenges can We're extreme growth products. at recently to expanded those initiatives move and we has from as about year. environment that We as markets, dissipating QX appear improving our weather we macro our to optimistic milestones continue much for at our the of
period our quarter on and very we've or range our able core turn wide a summary, and been review bit products; that for over momentum. confident device finally XXXX enhanced Moreover, time as results of very now will add and partnerships our of launch additional to to patients Our products of acquisitions. to unchanged. provide four development implantable short advance and we related fourth establish such, a can differentiated a With quite orthobiologic treating XXXX. three, synergistic for organization for to through sales accomplish in for standard we CanGaroo to undergoing expanding priorities in we're continues and believe next the continue we that, focused generation to vision second, to direct CanGaroo will our are In procedures. generating products build products; product; SimpliDerm; our continuing as proprietary on outlook care to clinical remain data contained for I the Matt first, a call a And we new and of of are opportunities
